Exercise of Options, Director/PDMR Dealing & TVR
Updated : 13:59
Instem plc
("Instem" or "the Company")
Exercise of Options, Director/PDMR Dealing and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it was notified on 4 January 2023 that certain of the Company's Directors and members of its senior management team exercised share options ("Share Options") over, in aggregate, 61,404 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). The Share Options were exercised on 4 January 2023 at an exercise price of £0.90 per Ordinary Share. The Share Options were granted on 14 January 2013 and would have lapsed if not exercised before 14 January 2023.
Subsequently, also on 4 January 2023, certain Directors sold the Ordinary Shares issued on the exercise of Share Options in their entirety at a price of £7.00 per Ordinary Share.
Details of the Directors (each of whom is a person discharging managerial responsibility or "PDMR") who exercised Share Options and subsequently sold Ordinary Shares are as follows:
Director | No. Share Options exercised | No. Ordinary Shares sold | Resultant interest in Ordinary Shares | Resultant interest in Ordinary Shares as a % of ISC |
Phil Reason, CEO | 23,429 | 23,429 | 770,714 | 3.39% |
Nigel Goldsmith, CFO | 15,000 | 15,000 | 10,000 | 0.04% |
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the admission of the 61,404 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 10 January 2023.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,765,712 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,765,712.
The figure of 22,765,712 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Instem plc | via Walbrook |
Singer Capital Markets (Nominated Adviser & Joint Broker) |
+44 (0) 20 7496 3000 |
Peter Steel Alex Bond | |
Oliver Platts
Stifel Nicolaus Europe Limited (Joint Broker) |
+44 (0) 20 7710 7600 |
Ben Maddison | |
Alex Price
| |
Walbrook Financial PR |
+44 (0) 20 7933 8780 |
Tom Cooper | instem@walbrookpr.com |
Nick Rome
|
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
a)
| Name
| Phil Reason | |||
2 | Reason for the notification | ||||
a)
| Position/status | CEO | |||
b)
| Initial notification /Amendment | Initial | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a)
| Name
| Instem plc | |||
b)
| LEI
| 213800PILYUFNNROQX68 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 10p each | |||
| |||||
Identification code | GB00B3TQCK30 | ||||
|
| ||||
b)
| Nature of the transaction | 1. Exercise of Options 2. Sale of Ordinary Shares | |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price | Volume(s) |
| |
|
| 1. 90p per Ordinary Share (exercise price) | 23,429 |
| |
|
| 2. 700p per Ordinary Share (sale price) | 23,429 |
| |
|
|
|
|
| |
d)
| Aggregated information | n/a - the exercise of options over Ordinary Shares and the sale of Ordinary Shares each completed as single transactions | |||
|
| ||||
- Aggregated volume |
| ||||
|
| ||||
- Price |
| ||||
|
| ||||
e)
| Date of the transaction | 4 January 2023 | |||
f) | Place of the transaction | In respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON) | |||
1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
a)
| Name
| Nigel Goldsmith | |||
2 | Reason for the notification | ||||
a)
| Position/status | CFO | |||
b)
| Initial notification /Amendment | Initial | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a)
| Name
| Instem plc | |||
b)
| LEI
| 213800PILYUFNNROQX68 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 10p each | |||
| |||||
Identification code | GB00B3TQCK30 | ||||
|
| ||||
b)
| Nature of the transaction | 1. Exercise of Options 2. Sale of Ordinary Shares | |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price | Volume(s) |
| |
|
| 1. 90p per Ordinary Share (exercise price) | 15,000 |
| |
|
| 2. 700p per Ordinary share (sale price) | 15,000 |
| |
|
|
|
|
| |
d)
| Aggregated information | n/a - the exercise of options over Ordinary Shares and the sale of Ordinary Shares each completed as single transactions | |||
| |||||
- Aggregated volume | |||||
| |||||
- Price | |||||
| |||||
e)
| Date of the transaction | 4 January 2023 | |||
f) | Place of the transaction | In respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON) | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.